• Institution: LOCKSS
LOCKSS

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

Figure 6
Figure 6

Representative heat map demonstrating anti-IFN-α, -IFNAR, and -IFN-ω mAb effects on healthy donor PBMC stimulated with serum from 1 SLE patient. Lane 1: SLE patient serum only; Lane 2: SLE patient serum plus reference antibody; Lane 3: SLE patient serum plus 10 μg/mL anti-IFN-ω mAb; Lanes 4–6: SLE patient serum plus increasing concentrations of anti-IFN-α mAb (0.1, 1, and 10 μg/mL); Lane 7: SLE patient serum plus 10 μg/mL anti-IFNAR mAb. Color represents relative neutralization (inhibition) of overexpression of individual genes upregulated by soluble mediators in the serum of an SLE patient. The red color represents no neutralization, and green represents neutralization of overexpression of individual genes. IFN = interferon; IFNAR = interferon associated receptor; PBMC = peripheral blood mononuclear cells; SLE = systemic lupus erythematosus.

This Article

  1. Hum Genomics Proteomics vol. 1 no. 1